COMMD3 and diffuse large B-cell lymphoma: The combination was well tolerated and had a predictable safety profile (n = 13; DLBCL-5, FL-2 and MCL-6). The R2PD for Bup and Ibru was 100 and 560 mg, respectively. For long-term therapy and tolerability, dose reduction might be required.Bup (80 mg) and Ibru (420 mg) (n = 6): 3 patients had a CR and 1 patient had SD.Bup (80 mg) and Ibru (560 mg) (n = 4): 1 patient had a CR and 2 patients had SD.Bup (100 mg) and Ibru (560 mg) (n = 3): 2 patients had PR.